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Abstract Aim of the review The translation of evidence
based medicine to a specific patient presents a considerable
challenge. We present by means of the examples nortrip-
tyline, tramadol, clopidogrel, coumarins, abacavir and
antipsychotics the discrepancy between available pharma-
cogenetic information and its implementation in daily
clinical practice. Method Literature review. Results A
mechanism based approach may be helpful to personalize
medicine for the individual patient to which pharmacoge-
netics may contribute significantly. The lack of consistency
in what we accept in bioequivalence and in pharmacoge-
netics of drug metabolising enzymes is discussed and
illustrated with the example of nortriptyline. The impact of
pharmacogenetics on examples like tramadol, clopidogrel,
coumarins and abacavir is described. Also the present
status of the polymorphisms of 5-HT2A and C receptors in
antipsychotic-induced weight gain is presented as a phar-
macodynamic example with until now a greater distance to
clinical implementation. Conclusion The contribution of
pharmacogenetics to tailor-made pharmacotherapy, which
especially might be of value for patients deviating from the
average, has not yet reached the position it seems to
deserve.
Keywords Drug metabolising enzymes  Mechanism
based medicine  Pharmacodynamics  Pharmacogenetics 
Pharmacokinetics
Introduction
Evidence based medicine applies guidelines developed on
the basis of consensus from randomized clinical trials
(RCTs). These RCTs are performed in carefully selected
patient-populations studied under strongly regulated con-
ditions. It often is a challenge to translate the results of the
RCTs to a specific patient in the real world [1]. In RCTs
often (young) people having one specific disease are
selected. In daily clinical practice a significant part of the
patients consists of elderly patients often having multiple
morbidities. For the majority of these patients still no
evidenced based medication is available. Therefore in these
situations there seems to be a need for a mechanism based
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approach towards medicine personalized for the individual
patient. In mechanism based medicine it is already com-
mon practice to adjust drug dose to age, liver and renal
function. Pharmacogenetics–the study of variations in
DNA sequence as related to drug response–is trying to
obtain its position among these factors [2]. Nevertheless we
experience a lack of enthusiasm in the implementation of
pharmacogenetics, especially when compared with for
instance adaptation of drug dosing to liver or renal function
or bodyweight for children.
Aim of the review
To review the evidence for the usefulness of pharmaco-
genetic information in relation to clinical implementation
of this pharmacogenetic information.
Method
We summarized the available information in the literature
for the pharmacogenetic information for nortriptyline
(CYP2D6), tramadol(CYP2D6), clopidogrel(CYP2C19),
coumarins(CYP2C9 and VKORC1), abacavir(HLA-
B*5701) and the relation between polymorphism of 5-HT2A
and C-receptors and antipsychotic induced weight gain as
typical examples and compared this with the clinical
implementation of these pharmacogenetic parameters. This
is put into the perspective of accepted differences in
bioequivalence.
Results/Discussion
In evidence based medicine the Guideline on the investi-
gation of bioequivalence (CPMP/EWP/QWP/1401/98
Rev.1/corr) is applied to assess whether generic medicines
are bioequivalent with the already marketed reference
drugs. In this guideline, bioequivalence is accepted if the
90% confidence interval of the ratio of the Area Under the
Curve (AUC) of the generic drug and the AUC of the
reference drug lies within 80.00–125.00%. For highly var-
iable drug products we accept extreme values up to
69.84–143.19% if this extent of variation is considered
clinically irrelevant as long as the geometric mean ratio lies
within 80.00–125.00%. With this in mind it is remarkable
that regulatory authorities do not require the application of
pharmacogenetics during the process of drug prescribing
and dispensing in the numerous examples of drugs for which
the AUC appears to deviate much stronger on a pharmaco-
genetic basis, as accepted in the above mentioned guideline.
Here we present such an example, discuss barriers for the
clinical implementation of pharmacogenetics and plea for a
more mechanism based approach to medicine.
A classic example of pharmacogenetics is the variability
in effect of the antidepressant nortriptyline due to different
genotypes. The plasma levels of nortriptyline may vary
almost tenfold depending on the number of functional
CYP2D6 allelles. Still we accept to use the same dose in
ultrarapid metabolisers for CYP2D6 (5–10% of the Cau-
casian population) and for intermediate and poor meta-
bolisers for CYP2D6 (15–25% of the Caucasian
population) as for the so called extensive metabolisers [3,
4]. In other words the same tablet of nortriptyline admin-
istered to a poor or intermediate metaboliser is not bio-
equivalent with the tablet administered to an extensive
metaboliser. Therefore, a one size fits all starting dose for
nortriptyline can not be considered an example of evidence
based medicine.
A second example for which from the perspective of
evidence based medicine it is hard to understand that
pharmacogenetics are not applied is tramadol, a l-receptor
agonist which also inhibits reuptake of serotonin and nor-
adrenaline [5]. This drug demonstrated efficacy in several
neuropathic pain conditions. However tramadol is a 50:50
mixture of (?)R,R- and (-)S,S-enantiomer which are O-
demethylated by CYP2D6 to the so called M1- metabolites
[6]. (?)- and (-)-Tramadol as well as (?)- and (-) -M1
strongly differ in affinity for the l-receptor, the noradren-
aline- and 5-HT-uptake [7]. This results in a different
pharmacological profile of tramadol for the different
CYP2D6 phenotypes. In ultrarapid and extensive meta-
bolisers tramadol has much more l-receptor agonist effect
than in poor metabolisers [8]. In the latter a more pro-
nounced noradrenaline- and 5-HT-uptake mediated effect
will be observed. The evidence for the successful treatment
of neuropathic pain with tramadol is based predominantly
on extensive metabolisers, because this is the largest phe-
notype group. However, in these patients we deal with
another active principle for tramadol than in patients with
variant genotypes for CYP2D6 where the effect will be
more dominated by the l-receptor agonistic (ultrarapid
metabolisers) or the noradrenaline- and the 5-HT-uptake
inhibiting effect (poor metabolisers). Therefore in the
Netherlands it is advised to select an alternative for tram-
adol in poor, ultrarapid and intermediate metabolisers for
CYP2D6 [3].
A third example is the antiplatelet drug clopidogrel. In
evidence based medicine one often develops pharmaco-
therapeutic strategies based on post hoc or subgroup
analysis of large randomized clinical trials. However,
before applying pharmacogenetic knowledge from post hoc
analysis, in daily clinical practice one calls for additional
randomized studies. Prasugrel, another antiplatelet drug,
was compared to clopidogrel in over 13,000 patients with
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an acute coronary syndrome undergoing a percutaneous
coronary intervention (PCI) in the TRITON-TIMI 38 study
[9]. In a post hoc analysis in approximately 3,500 patients
with ST segment elevation myocardial infarction (STEMI),
prasugrel appeared to be more effective than clopidogrel in
preventing the occurrence of cardiovascular ischemic
events without an increased risk of developing bleedings
[10]. The NICE appraisal recommends prasugrel as an
option when immediate PCI for STEMI is necessary. In
another post hoc analysis including clopidogrel treated
patients of the TRITON-TIMI 38 study, the influence of
genetic variants of CYP2C19 on the occurrence of car-
diovascular ischemic events was studied. Clopidogrel is a
prodrug which requires biotransformation to the active
metabolite by the polymorphic CYP2C19. Carriage of
genetic variants encoding for non functional CYP2C19
enzyme was associated with an increased risk of stent
thrombosis and the combined endpoint of cardiovascular
death, myocardial infarction or stroke [11]. This associa-
tion was also observed in other studies and recently even
resulted in a boxed warning by the FDA about the reduced
effectiveness of clopidogrel in homozygous carriers of a
CYP2C19 non functional allele. Nevertheless experts do
not recommend routine genetic testing yet since there is no
or limited information regarding the predictive value of
genetic testing and the effect of a genotype guided treat-
ment strategy on clinical outcome based on the results of
randomized studies with sufficient power [12].
Besides genetically determined differences in pharma-
cokinetics, the variability in drug response can also be
attributed to genetic variability in factors influencing drug
action, for example, the drug receptor level (pharmacody-
namics) [13]. As an example, in psychiatric pharmaco-
therapy at least two subtypes of the serotonin (5-HT)
receptor have shown to be important: the 5-HT2A and the
5-HT2C receptor [14–16]. Polymorphisms in the HTR2C
gene coding for the 5-HT2C receptor are of interest
because of the association between HTR2C polymorphisms
and the response of antipsychotic drugs [17] but also
because of the association between HTR2C polymorphisms
and antipsychotic-induced weight gain [16]. The transla-
tion to the corresponding clinical phenotype of pharma-
codynamic polymorphisms like HTR2C is more complex
than the translation of pharmacokinetic polymorphisms
like CYP2D6. The consequences of pharmacokinetic
polymorphisms can quite easily be measured with standard
pharmacokinetic parameters (surrogate endpoints) like
the steady state concentration, elimination half-live and the
area under the curve (AUC) of administered drugs.
The consequences of pharmacodynamic polymorphisms
are more difficult to measure [13]. The pharmacodynamic
polymorphisms have to be translated to a clinical pheno-
type based upon the expected function of the gene where
the polymorphism is located. One of the limitations of this
approach is that the clinical phenotype as a result of gene
expression is not well known for many drug targeting
receptors. The gene coding for the 5-HT2c receptor is an
example of a drug targeting receptor with a relatively
unknown phenotype. One of the suggested clinical phe-
notypes of the HTR2C gene is a function in regulation of
food intake and weight gain but results are conflicting
[18–25]. This pharmacodynamic polymorphism is one
example of many others. However, the difficulties as
described above impede implementation of genotyping of
pharmacodynamic in contrast to pharmacokinetic poly-
morphisms in daily clinical practice at this moment.
Especially pharmacokinetic examples illustrate the dis-
crepancy between the generally accepted limits for bio-
equivalence applied by the regulatory authorities and their
position taken in pharmacogenetics. However, there are
examples where the regulatory authorities took a clear
standpoint with respect to the application of pharmacoge-
netics. Because of the increased risk of hypersensitivity
reactions, on March 10, 2008 the CBG-MEB has revised
the Summary of Product Characteristics of abacavir to
include the advise to screen for HLA-B*5701 prior to
treatment initiation and that abacavir should not be used in
carriers of this polymorphism, unless there is no thera-
peutic alternative. An overview of drugs with a pharmac-
ogenomic labelling from EMA and FDA for which
genotyping is recommended or required can be found for
instance in the paper of Becquemont [26]. Also the draft
Guideline on the use of pharmacogenetic methodologies in
the pharmacokinetic evaluation of medicinal products from
the EMA (EMA/CHMP/37646/2009) reflects a clear role
for pharmacogenetics in the evaluation of efficacy and
safety of drugs as considered by the regulatory authority.
Where are we standing now? The current use of geno-
typing is mostly limited to diagnostics with a focus on
adverse drug events in individual patients. Prevention of
toxicity and treatment optimization through prospective
screening is still far from being common practice. How-
ever, there are major developments in the field. Multiple
relatively rare adverse drug events such as flucloxacilline-
induced liver injury [27], Stevens-Johnson syndrome
induced by carbamazepine [28], and the hypersensitivity
reaction to abacavir [29] have all been associated with
specific HLA-B genotypes. For the latter, a prospective
study showed that the hypersensitivity reaction can be
prevented by screening patients prior to treatment with
abacavir [29].
Furthermore, pharmacogenetic research has progressed
from searching for associations between individual SNPs
and treatment outcome, through combinations of multiple
SNPs affecting pharmacokinetics and pharmacodynamics,
to the use of pharmacogenetic models including SNPs as
Int J Clin Pharm (2013) 35:369–375 371
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well as more traditional clinical variables such as age, renal
function and bodyweight. The inclusion of these traditional
clinical variables is essential since individuals belonging to
the same pharmacogenetic class still may vary about 10-
fold in metabolic ratio, demonstrating that pharmacoge-
netics can not explain all interindividual differences, but is
only one additional component [30].
For the coumarins much clinical evidence is present
(especially from observational research) for the added value
of knowledge of the genotype of CYP2C9 and VKORC1 for
safe application which is not reflected yet in clinical
application (see e.g. [31, 32]). The progress from individual
SNPs to pharmacogenetic models is well exemplified by the
coumarin warfarin. This drug is metabolised by the poly-
morphic enzyme CYP2C9. The CYP2C9 genotype alone
explained 5–18% of the variation in required warfarin dose
[33]. It was already reported that genetic variability in
VKORC1, a gene coding for vitamine K epoxide reductase,
a key enzyme in the vitamine K cycle, could explain
15–37% of the variation in required warfarin dose [34–37].
Recently models including genetic variants of VKORC1,
CYP2C9 and clinical factors such as age, sex, height and
bodyweight have been reported to explain up to 50% of
variation in required warfarin dose [38].
We know that genotyping can give useful information
for the prescription of certain drugs which could lead to a
balanced use of genotyping. It should be emphasized that
the role of pharmacogenetics may be more compelling if at
the start of therapy with a new drug a quick finding of the
right dose is of importance or in cases where hypersensi-
tivity reactions are involved. If there is chosen for the
approach of starting with an almost universally tolerated
dose, which then is gradually increased until the desired
effects are achieved or the onset of unacceptable side
effects, the advantage of the application of pharmacoge-
netics may be less pronounced although even then a more
appropriate, tailor made starting dose may be selected.
Also Therapeutic Drug Monitoring could be improved by
Table 1 Examples of therapeutic (dose) recommendations




Therapeutic (dose) recommendation References
Tramadol (CYP2D6) PM Yes Select alternative drug (e.g. acetaminophen, NSAID, morphine NOT
oxycodone or codeine) or be alert to symptoms of insufficient pain
relief
[43–48]
IM Yes Select alternative drug (e.g. acetaminophen, NSAID, morphine NOT
oxycodone or codeine) or be alert to symptoms of insufficient pain
relief
[43, 44, 49]
UM Yes Select alternative drug (e.g. acetaminophen, NSAID, morphine NOT
oxycodone or codeine) or be alert to ADE (e.g. nausea, vomiting,




*1/*2 Yes Standard loading dose. Reduce maintenance dose by 25%. Evaluate
response and serum concentration after 7–10 days. Be alert to ADE
(e.g. ataxia, nystagmus, dysarthria, sedation)
[51–57]
*1/*3 Yes Standard loading dose. Reduce maintenance dose by 25%. Evaluate
response and serum concentration after 7–10 days. Be alert to ADE
(e.g. ataxia, nystagmus, dysarthria, sedation)
[51–55, 58–65]
*2/*2 Yes Standard loading dose. Reduce maintenance dose by 50%. Evaluate
response and serum concentration after 7–10 days. Be alert to ADE
(e.g. ataxia, nystagmus, dysarthria, sedation)
[51–54, 56, 57]
*2/*3 Yes Standard loading dose. Reduce maintenance dose by 50%. Evaluate
response and serum concentration after 7–10 days. Be alert to ADE
(e.g. ataxia, nystagmus, dysarthria, sedation)
[52, 57]
*3/*3 Yes Standard loading dose. Reduce maintenance dose by 50%. Evaluate
response and serum concentration after 7–10 days. Be alert to ADE
(e.g. ataxia, nystagmus, dysarthria, sedation)




PM Yes No [70–76]
IM Yes No [72, 73, 75–77]
UM Yes Monitor plasma concentration and titrate dose to max. 150% in
response to efficacy and ADE or select alternative drug (e.g.
fluoxetine, paroxetine)
[73, 78]
For a complete list of therapeutic (dose) recommendations see ref. [3]
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including genetic information. Pharmacogenetics may
increase benefit and reduce harm in people whose drug
response is not ‘average’ [39]. However, clinical imple-
mentation remains limited [40]. Maybe the cause of the
slow integration of pharmacogenetic testing in clinical
practice to improve dosing and minimize safety risks is the
urge for appropriate education of prescribing physicians,
ethics committees, and investigators on the use and inter-
pretation of the pharmacogenetic information provided in
the drug label [41]. The above mentioned example of the
coumarins seems to indicate that clinical evidence does not
suffice to implement pharmacogenetics in daily practice,
but first mega-trials have to be performed [31]. The
availability of the genotype information and the connected
turn around time for the lab are also often referred to, but
are solvable problems. The pronounced discussion on cost-
effectiveness in the field of genotyping contrasts with the
implementation of specific requirements for e.g. drug
dosing in children or therapeutic drug monitoring. Fur-
thermore it is highly likely that this cost discussion will
fade away in the not so distant future since the costs of
genotyping are dropping every day [42]. Between 10 and
20 years from now we will probably all have our DNA
sequence available in medical records. By then genotyping
costs will no longer be important, however it will be even
more important to have guidelines on how to clinically
make use of all this information.
To support the implementation of pharmacogenetics, the
Royal Dutch Association for the Advancement of Phar-
macy (KNMP) installed a multidisciplinary working group
with the objective to develop pharmacogenetics-based
therapeutic (dose) recommendations based upon a sys-
tematic review of the literature and to assist prescribers by
integrating the recommendations into computerized sys-
tems for prescribing and automated medication surveil-
lance [3]. These data are electronically available to all
pharmacists in the Netherlands. Examples of these are
provided in Table 1. For each genotype/phenotype-drug
combination it is clearly stated whether there is an inter-
action or not with the polymorphism specified and which
action is required. It would contribute to medication safety
if in those cases were genotyping results in adaptation of
pharmacotherapy, genotyping would indeed be performed.
Conclusion
In conclusion, evidence based medicine still aims at an
average patient from a carefully selected patient popula-
tion, but does not do justice to the individual characteristics
of patients. If one adds knowledge of the mechanisms of
pathology, knowledge of mechanism of action of drugs,
both pharmacodynamically and pharmacokinetically, as
well as the knowledge of the individual patient including
his pharmacogenetic characteristics if relevant for the
pharmacotherapy considered, the result will be a tailor-
made pharmacotherapy. This might be considered a com-
modity in the current era so strongly characterised by an
emphasis on attention for medication safety.
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